Comparison of Efficacy of Sibutramine or Orlistat Versus Their Combination in Obese Women

Sarı, Ramazan; Balcı, Mustafa Kemal; Çakır, Mehtap; Altunbaş, Hasan; Karayalçın, Ümit

doi:10.1081/erc-200027356

Cited by 38 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identical effectiveness of both continuous and intermittent drug administration was demonstrated for several anti-obesity drugs (47). Combination treatment with sibutramine and orlistat does not influence weight loss (48). However, in the future, combination therapy with anti-obesity drugs should be expected.…”

Section: Psychological Factors and Behavioralmentioning

confidence: 99%

Treatment Modalities of Obesity

2008

View full text Add to dashboard Cite

The prevalence of obesity is increasing in both developed and developing countries, with rates reaching ϳ10 -35% among adults in the Euro-American region. Obesity is associated with increased risks of cardiovascular diseases, type 2 diabetes, arthritis, and some type of cancers. Obesity significantly affects the quality of life and reduces the average life expectancy. The effective treatment of obesity should address both the medical and the social burden of this disease. Obesity needs to be treated within the health care system as any other complex disease, with empathy and without prejudice. Both health care providers and patients should know that the obesity treatment is a lifelong task. They should also set realistic goals before starting the treatment, whereas keeping in mind that even a modest weight loss of 5-15% significantly reduces obesity-related health risks. Essential treatment of obesity includes low-calorie low-fat diets, increased physical activity, and strategies contributing to the modification of lifestyle. Anti-obesity drugs facilitate weight loss and contribute to further amelioration of obesity-related health risks. A short-term weight loss, up to 6 months, is usually achieved easily. However, the long-term weight management is often associated with a lack of compliance, failures, and a high dropout rate. Regular physical activity, cognitive behavioral modification of lifestyle, and administration of anti-obesity drugs improve weight loss maintenance. Bariatric surgery is an effective strategy to treat severely obese patients. Bariatric surgery leads to a substantial improvement of comorbidities as well as to a reduction in overall mortality by 25-50% during the long-term follow-up. Obesity treatment should be individually tailored and the following factors should be taken into account: sex, the degree of obesity, individual health risks, psychobehavioral and metabolic characteristics, and the outcome of previous weight loss attempts. In the future, an evaluation of hormonal and genetic determinants of weight loss could also contribute to a better choice of individual therapy for a particular obese patient. A multilevel obesity management network of mutually collaborating facilities should be established to provide individually tailored treatment. Centers of excellence in obesity management represented by multidisciplinary teams should provide comprehensive programs for the treatment of obesity derived from evidence-based medicine. Diabetes Care 31 (Suppl. 2):S269-S277, 2008T he prevalence of obesity is increasing worldwide at an alarming rate in both developed and developing countries (1). European obesity prevalences range from 10 to 20% in men and 15 to 25% in women, whereas the prevalence of obesity among U.S. adults has reached 28% in men and 34% in women.Excess body weight is the sixth most important risk factor contributing to the health burden of the world. Obesity amplifies the risks of type 2 diabetes, hypertension, cardiovascular disease, dyslipidemia, arthritis, and several canc...

show abstract

Section: Psychological Factors and Behavioralmentioning

confidence: 99%

Treatment Modalities of Obesity

2008

View full text Add to dashboard Cite

show abstract

“…Sibutramine (10-20 mg/day for 12 weeks to 12 months) reduced body weight and BMI more than orlistat (360 mg/day) in three studies in obese patients (total n = 325). [133][134][135] However, in two other studies (total n = 259), sibutramine (10 mg/day given for 12-24 weeks) and orlistat (360 mg/day) induced similar reductions in body weight, BMI, and waist circumference. 136,137 In another study in 115 hypertensive obese patients, sibutramine (10 mg/day given for 12 months) and orlistat (360 mg/day) reduced body weight, BMI, waist circumference and WHR to a similar extent.…”

Section: Comparative Studies With Other Antiobesity Agentsmentioning

confidence: 99%

“…138,140 Combining sibutramine and orlistat (10 mg and 360 mg/day, respectively, for 3-6 months) did not provide additional benefits over sibutramine monotherapy in obese patients. 133,134 Interestingly, a small study in 34 women who had received sibutramine for one year showed that adding orlistat to sibutramine for 16 weeks did not induce further weight loss. 141 In another study in 198 obese patients, combining sibutramine with an experimental selective antagonist of the receptor 5 of the orexigenic neuropeptide Y did not result …”

Section: Comparative Studies With Other Antiobesity Agentsmentioning

confidence: 99%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

“…A third study, also of 6 months' duration, randomized 89 obese women to orlistat, sibutramine, or the combination and showed weight losses of 5.5, 10.1, and 10.8 kg, respectively. The combination was superior to orlistat but not to sibutramine alone (Sari et al, 2004). A fourth study randomized 86 obese subjects to 10 mg/day of sibutramine, 360 mg/day of orlistat, the combination, or diet alone.…”

Section: Studies In Childrenmentioning

confidence: 99%